Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Trimeprazine increases IRS2 in human islets and promotes pancreatic β cell growth and function in mice
Alexandra Kuznetsova, Yue Yu, Jennifer Hollister-Lock, Lynn Opare-Addo, Aldo Rozzo, Marianna Sadagurski, Lisa Norquay, Jessica E. Reed, Ilham El Khattabi, Susan Bonner-Weir, Gordon C. Weir, Arun Sharma, Morris F. White
Alexandra Kuznetsova, Yue Yu, Jennifer Hollister-Lock, Lynn Opare-Addo, Aldo Rozzo, Marianna Sadagurski, Lisa Norquay, Jessica E. Reed, Ilham El Khattabi, Susan Bonner-Weir, Gordon C. Weir, Arun Sharma, Morris F. White
View: Text | PDF
Research Article Endocrinology Metabolism

Trimeprazine increases IRS2 in human islets and promotes pancreatic β cell growth and function in mice

  • Text
  • PDF
Abstract

The capacity of pancreatic β cells to maintain glucose homeostasis during chronic physiologic and immunologic stress is important for cellular and metabolic homeostasis. Insulin receptor substrate 2 (IRS2) is a regulated adapter protein that links the insulin and IGF1 receptors to downstream signaling cascades. Since strategies to maintain or increase IRS2 expression can promote β cell growth, function, and survival, we conducted a screen to find small molecules that can increase IRS2 mRNA in isolated human pancreatic islets. We identified 77 compounds, including 15 that contained a tricyclic core. To establish the efficacy of our approach, one of the tricyclic compounds, trimeprazine tartrate, was investigated in isolated human islets and in mouse models. Trimeprazine is a first-generation antihistamine that acts as a partial agonist against the histamine H1 receptor (H1R) and other GPCRs, some of which are expressed on human islets. Trimeprazine promoted CREB phosphorylation and increased the concentration of IRS2 in islets. IRS2 was required for trimeprazine to increase nuclear Pdx1, islet mass, β cell replication and function, and glucose tolerance in mice. Moreover, trimeprazine synergized with anti-CD3 Abs to reduce the progression of diabetes in NOD mice. Finally, it increased the function of human islet transplants in streptozotocin-induced (STZ-induced) diabetic mice. Thus, trimeprazine, its analogs, or possibly other compounds that increase IRS2 in islets and β cells without adverse systemic effects might provide mechanism-based strategies to prevent the progression of diabetes.

Authors

Alexandra Kuznetsova, Yue Yu, Jennifer Hollister-Lock, Lynn Opare-Addo, Aldo Rozzo, Marianna Sadagurski, Lisa Norquay, Jessica E. Reed, Ilham El Khattabi, Susan Bonner-Weir, Gordon C. Weir, Arun Sharma, Morris F. White

×

Figure 3

Trimeprazine tartrate (20 mg/l) was analyzed using the Cellular Functional GPCR Profile covering 30 different GPCRs.

Options: View larger image (or click on image) Download as PowerPoint
Trimeprazine tartrate (20 mg/l) was analyzed using the Cellular Function...
Agonist (A) and antagonist (B) measurements were conducted in duplicate, and the data points are shown as white circles with a bar for the SD. Results showing a stimulation or an inhibition higher than 50% (above gray bar) were considered significant (*) on the basis of historical data at Cerep. Measurements between 25% and 50% indicate weak-to-moderate effects that were not considered significant. The receptors are grouped by the assay read-out: IP1 (inositol phosphate 1); IMP (electrical impedance); cAMP (cyclic adenosine monophosphate); or Ca2+. “NSI” indicates that the test compound interfered nonspecifically in the assay judged, because the signal observed was very different from the signal of the reference agonist, suggesting that the compound acts through a different pathway. “AGO” indicates that the test compound induced at least a 25% agonist or agonist-like effect at this concentration, so further addition of the reference agonist could not produce a full response (partial agonist), which resulted in an apparent inhibition. (C) The average relative expression of the selected GPCRs taken from publicly available Affymetrix CEL files (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50398) was normalized against GLP1R expression. The expression profiles were analyzed using RMA16 in GeneSpring, version 12.6. The GPCR/GLP1R below the median is highlighted in the gray box. (D) *P < 0.05. Pearson’s correlation coefficient for the expression of each GPCR against IRS2 expression calculated using Analyze-it. The 2-sided 95% CIs were determined by Fisher’s Z test. Inset shows the correlation coefficient between IRS2 and either GLP1R or PDX1. HTR2B, 5-hydroxytryptamine (serotonin) receptor 2B; HTR2A, 5-hydroxytryptamine (serotonin) receptor 2A; HTR2C, 5-hydroxytryptamine (serotonin) receptor 2C; HTR1D, 5-hydroxytryptamine (serotonin) receptor 1D; OPRD1, opioid receptor δ 1; OPRK1, opioid receptor κ 1; OPRM1, opioid receptor μ 1; ADRA2C, adrenergic α-2C receptor; CHRM4, cholinergic receptor muscarinic 4; DRD3, dopamine receptor D3; DRD4, dopamine receptor D4; CHRM2, cholinergic receptor muscarinic 2; ADORA3, adenosine A3 receptor; ADORA2B, adenosine A2b receptor; ADRB1, adrenergic β-1 receptor; DRD1, dopamine receptor D1; HRH2, histamine receptor H2; HTR4, 5-hydroxytryptamine (serotonin) receptor 4; ADORA2A, adenosine A2a receptor; CCKAR, cholecystokinin A receptor; ADRA1B, adrenergic α-1B receptor; ADRB2, adrenergic β-2 receptor surface; HTR6, 5-hydroxytryptamine (serotonin) receptor 6; HTR7, 5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase–coupled); TACR1, tachykinin receptor 1; HRH1, histamine receptor H1; CHRM5, cholinergic receptor, muscarinic 5; ADRA1A, adrenergic α-1A receptor; CHRM1, cholinergic receptor muscarinic 1; CHRM3, cholinergic receptor muscarinic 3; IRS2, insulin receptor substrate 2.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts